The establishment of supramolecular immunobead real-time PCR and the identification of Cox-2 as a metastasis-related marker in colorectal carcinoma

Li,Zu-Guo; Wang,Xiao-Yan; Chang,Jian-Lan; Xie,Wei-Bing; Liu,Teng-Fei; Zhang,Qing-Ling; Deng,Yong-Jian; Ding,Yan-Qing

doi:10.3892/or.2012.1867

The establishment of supramolecular immunobead real-time PCR and the identification of Cox-2 as a metastasis-related marker in colorectal carcinoma

Authors:
- Zu-Guo Li
- Xiao-Yan Wang
- Jian-Lan Chang
- Wei-Bing Xie
- Teng-Fei Liu
- Qing-Ling Zhang
- Yong-Jian Deng
- Yan-Qing Ding
View Affiliations

Affiliations: Department of Pathology, Nanfang Hospital, Southern Medical University; Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China
Published online on: June 15, 2012 https://doi.org/10.3892/or.2012.1867
Pages: 977-984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclooxygenase-2 (Cox-2) is an inducible enzyme that converts arachidonic acid to prostaglandins, and it is hypothesized to induce carcinogenesis and metastasis in colorectal cancer. Our previous data also indicated that a higher expression level of Cox-2 was correlated with colorectal cancer metastasis. The Cox-2 protein was detected in the glandular cavity of colorectal cancer and the surrounding interstitial tissues. The usefulness of the Cox-2 gene as a gene therapy target and diagnostic marker remains unknown. In this study, a method using immuno-PCR and real-time PCR followed by supramolecular immunobead real-time PCR was established and used to detect the expression of Cox-2 in serum samples of nude mice with colorectal carcinoma. In addition, we established a Cox-2 gene stable knockdown colorectal cell line (SW480-EGFP-Cox-2 shRNA) using lentiviral vector-mediated RNA interference (RNAi) technology and established an imageable colorectal cancer metastasis mouse model. We found that the proliferation, invasion and tumorigenesis of SW480-EGFP-Cox-2 shRNA cells were attenuated compared with SW480 cells. In vivo experiments also demonstrated that angiogenesis in the Cox-2 knockdown colorectal cancer cells was decreased. The whole body optical imaging revealed that the SW480-EGFP-Cox-2 shRNA cells had an abrogated ability to develop metastases in the lymph nodes, lungs or liver in vivo. The improved immunobead PCR assay detected significantly lower Cox-2 protein levels in the serum samples of the SW480-EGFP-Cox-2 shRNA group compared with those of the SW480-EGFP-Cox-2-Ctrl shRNA group. In conclusion, our results indicated that the knockdown of Cox-2 expression suppressed the proliferation and invasion of colorectal cancer cells both in vitro and in vivo. This study also demonstrated that silencing Cox-2 in vivo reduced the metastastic potential of colorectal cancer. Thus, Cox-2 is a promising marker for the diagnosis of colorectal metastasis and a potential therapeutic target for colorectal cancer.

View Figures

View References

1	Masunaga R, Kohno H, Dhar DK, et al: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 6:4064–4068. 2000.
2	Wendum D, Masliah J, Trugnan G and Fléjou JF: Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch. 445:327–333. 2004.
3	Möbius C, Stein HJ, Spiess C, et al: COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol. 31:755–759. 2005.
4	Wang Q, Takei Y, Kobayashi O, Osada T and Watanabe S: Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J Clin Biochem Nutr. 45:163–170. 2009.
5	Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: Cox-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 90:423–429. 2004.
6	Singh B, Berry JA, Shoher A, Ramakrishnan V and Lucci A: Cox-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 26:1393–1399. 2005.
7	Wang W, Bergh A and Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res. 11:3250–3256. 2005.
8	Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C and Eicheler W: Cox-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res. 22:1225–1230. 2002.
9	Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.
10	Kim JY, Lim SJ and Park K: Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. Appl Immunohistochem Mol Morphol. 12:67–70. 2004.
11	Li ZG, Liu TF, Xie WB, Zhou J, Yu L and Ding YQ: Association of abnormal cyclooxygenase-2 gene expression with colorectal carcinoma metastasis. Nan Fang Yi Ke Da Xue Xue Bao. 26:1408–1411. 2006.(In Chinese).
12	Dempke W, Rie C, Grothey A and Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer Res Clin Oncol. 127:411–417. 2001.
13	Narayanan BA, Narayanan NK, Pttman B and Reddy BS: Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate. 66:257–265. 2006.
14	Yao M, Kargman S, Lam EC, et al: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 63:586–592. 2003.
15	Bottone FG Jr, Martinez JM, Collins JB, Afshari CA and Eling TE: Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J Biol Chem. 278:25790–25801. 2003.
16	Dubé C, Rostom A, Lewin G, et al: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 146:365–375. 2007.
17	Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of Cox-2. N Engl J Med. 356:2131–2142. 2007.
18	Oshima M, Murai N, Kargman S, et al: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:1733–1740. 2001.
19	Rashidi B, Gamagami R, Sasson A, Sun FX, Geller J, Moossa AR and Hoffman RM: An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res. 6:2556–2561. 2000.
20	Cao Y, Pearman AT, Zimmerman GA, McIntyre TM and Prescott SM: Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 97:11280–11285. 2000.
21	Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y and Mori H: Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res. 88:1044–1051. 1997.
22	Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A and Mori H: Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res. 90:406–412. 1999.
23	Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000.
24	Caplen NJ, Parrish S, Imani F, Fire A and Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 98:9742–9747. 2001.
25	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001.
26	Soutschek J, Akinc A, Bramlage B, Charisse K, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432:173–178. 2004.
27	Lu PY, Xie F and Woodle MC: In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet. 54:117–142. 2005.
28	Charames GS and Bapat B: Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol. 28:543–549. 2006.
29	Bartosch B and Cosset FL: Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther. 4:427–443. 2004.
30	Bailey SN, Ali SM, Carpenter AE, Higgins CO and Sabatini DM: Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods. 3:117–122. 2006.
31	Abbas-Terki T, Blanco-Bose W, Déglon N, Pralong W and Aebischer P: Lentiviral-mediated RNA interference. Hum Gene Ther. 13:2197–201. 2002.
32	Niemeyer CM, Wacker R and Adler M: Combination of DNA-directed immobilization and immuno-PCR: very sensitive antigen detection by means of self-assembled DNA-protein conjugates. Nucleic Acids Res. 31:e902003.
33	Grinde B, Jonassen T and Ushijima H: Sensitive detection of group A rotaviruses by immunomagnetic separation and reverse transcription-polymerase chain reaction. J Virol Methods. 55:327–338. 1995.
34	Xiang CQ, Shen CL, Wu ZR, Qin YQ, Zhang YY, Liu CZ, Chen JG and Zhang SN: Detection of mutant p53 protein in workers occupationally exposed to benzidine. J Occup Health. 49:279–284. 2007.